DCTPepD_ID,Active_ingredients,PubChem_CID,DRUGBANK_Accession_Number,NCI_Thesaurus_Code,Synonyms,Sequence,Sequence_Length,Other_Modification,Molecular_Formula,Molecular_Weight,IUPAC_Name,Classification,Type,Description,UNII,CAS,InChI,InChI_Key,SMILES,Disease,Indication
DCTPepD0003,Octreotide,6400441,DB00104,C711,SMS-201-995; D-Phenylalanyl-L-cysteinyl-L-phenyl-alanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide Cyclic (2->7)-Disulfide; Octreotide,FCFWKXCT,8,"X=xiThr, N-terminal ol",C49H66N10O10S2,1019.247,"(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide",Somatostatin and analogues##Peptide and derivative##Cyclic,Biotech,"A synthetic long-acting cyclic octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Octreotide is a more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Similar to somatostatin, this agent also suppresses the luteinizing hormone response to gonadotropin-releasing hormone, decreases splanchnic blood flow, and inhibits the release of serotonin, gastrin, vasoactive intestinal peptide (VIP), secretin, motilin, pancreatic polypeptide, and thyroid stimulating hormone.",RWM8CCW8GP,83150-76-9,"InChI=1S/C49H66N10O10S2/c1-28(61)39(25-60)56-48(68)41-27-71-70-26-40(57-43(63)34(51)21-30-13-5-3-6-14-30)47(67)54-37(22-31-15-7-4-8-16-31)45(65)55-38(23-32-24-52-35-18-10-9-17-33(32)35)46(66)53-36(19-11-12-20-50)44(64)59-42(29(2)62)49(69)58-41/h3-10,13-18,24,28-29,34,36-42,52,60-62H,11-12,19-23,25-27,50-51H2,1-2H3,(H,53,66)(H,54,67)(H,55,65)(H,56,68)(H,57,63)(H,58,69)(H,59,64)/t28-,29?,34-,36+,37+,38-,39-,40+,41+,42+/m1/s1",DEQANNDTNATYII-RRCPSWKPSA-N,CC([C@@H]1NC([C@@H](NC([C@H](NC([C@@H](NC([C@H](CSSC[C@H](NC1=O)C(N[C@@H]([C@H](O)C)CO)=O)NC([C@@H](CC2=CC=CC=C2)N)=O)=O)CC3=CC=CC=C3)=O)CC4=CNC5=CC=CC=C45)=O)CCCCN)=O)O,"Acromegaly, Diarrhea, Metastatic Carcinoid Tumors",Octreotide by injection is used for the treatment of acromegaly and the reduction of flushing and diarrhea symptoms related to carcinoid tumors and/or vasoactive intestinal peptide (VIPoma) tumors. The delayed-release oral formulation is used for the long-term treatment of acromegaly in patients who tolerate and respond adequately to injectable octreotide and lanreotide.
DCTPepD0005,Lanreotide,6918011,DB06791,C1523,"Abarelix; Plenaxis; Angiopeptin; BIM-23014; DC 13116; Dermopeptin; Ipstyl; L-Threoninamide, 3-(2-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2-7)-disulfide; Nal-cyclo(cys-tyr-trp-lys-val-cys)-thr-NH2; Somatulina; Somatuline; Lanreotide",XCYWKVCX,8,"X(1)=2Nal, X(8)=xiThr, N-terminal NH2",C54H69N11O10S2,1096.333,3-(2-naphthyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide (2->7)-disulfide,Somatostatin and analogues##Peptide and derivative##Hormone and analogue,Small Molecule,"A synthetic cyclic octapeptide analogue of somatostatin. Lanreotide binds to somatostatin receptors (SSTR), specifically SSTR-2 and also to SSTR-5 with a lesser affinity. However, compare with octreotide, this agent is less potent in inhibiting the release of growth hormone from the pituitary gland. Furthermore, lanreotide has an acute effect on decreasing circulating total and free insulin-like growth factor 1 (IGF-I). This agent is usually given as a prolonged-release microparticle or Autogel formulation for the treatment of acromegaly and to relieve the symptoms of neuroendocrine tumors.",0G3DE8943Y,108736-35-2,"InChI=1S/C54H69N11O10S2/c1-29(2)45-54(75)63-44(53(74)65-46(30(3)66)47(57)68)28-77-76-27-43(62-48(69)38(56)23-32-15-18-33-10-4-5-11-34(33)22-32)52(73)60-41(24-31-16-19-36(67)20-17-31)50(71)61-42(25-35-26-58-39-13-7-6-12-37(35)39)51(72)59-40(49(70)64-45)14-8-9-21-55/h4-7,10-13,15-20,22,26,29-30,38,40-46,58,66-67H,8-9,14,21,23-25,27-28,55-56H2,1-3H3,(H2,57,68)(H,59,72)(H,60,73)(H,61,71)(H,62,69)(H,63,75)(H,64,70)(H,65,74)",PUDHBTGHUJUUFI-UHFFFAOYSA-N,CC(C1NC(C(NC(C(NC(C(NC(C(CSSCC(NC1=O)C(NC(C(O)C)C(N)=O)=O)NC(C(CC2=CC=C3C=CC=CC3=C2)N)=O)=O)CC4=CC=C(C=C4)O)=O)CC5=CNC6=CC=CC=C56)=O)CCCCN)=O)C,"Gastroenteropancreatic neuroendocrine tumors, Acromegaly","Lanreotide is indicated for the long-term treatment of patients with acromegaly who have had an inadequate response to, or cannot be treated with, surgery and/or radiotherapy. It is also indicated in the treatment of adult patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival.<br>Lanreotide is additionally indicated for the treatment of adults with carcinoid syndrome - when used, it reduces the frequency of short-acting somatostatin analog rescue therapy."
DCTPepD0008,Somatostatin,16129706,DB09099,C836,AY 24910; GH-RIH; Growth Hormone Inhibiting Hormone; Panhibin; Recombinant Somatostatin; Somatostatin,AGCKNFFWKTFTSC,14,None,C76H104N18O19S2,1637.895,"(4R,7S,10S,13S,16S,19S,22S,25S,28S,31S,34S,37R)-19,34-bis(4-aminobutyl)-37-{2-[(2S)-2-aminopropanamido]acetamido}-13,25,28-tribenzyl-31-(carbamoylmethyl)-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-22-[(1H-indol-3-yl)methyl]-6,9,12,15,18,21,24,27,30,33,36-undecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35-undecaazacyclooctatriacontane-4-carboxylic acid",Somatostatin and analogues##Peptide and derivative##Hormone and analogue##Cyclic,Small Molecule,"Somatostatin, also known as growth hormone-inhibiting hormone, is a naturally-occurring peptide hormone of 14 or 28 amino acid residues that regulates the endocrine system. It is secreted by the D cells of the islets to inhibit the release of insulin and glucagon, and is also generated in the hypothalamus, where it inhibits the release of growth hormone and thyroid-stimulating hormones from the anterior pituitary. Somatostatin is initially secreted as a 116 amino acid precursor, preprosomatostatin, which undergoes endoproteolytic cleavage to prosomastatin. Prosomastatin is further process into two active forms, somatostatin-14 (SST-14) and somatostatin-28 (SST-28), an extended SST-14 sequence to the N-terminus. The actions of somatostatin are mediated via signalling pathways of G protein-coupled somatostatin receptors. Antineoplastic effects and potential uses of somatostatin on various tumours, including pituitary adenomas, GEP-NETs, paragangliomas, carcinoids, breast cancers, malignant lymphoma and small-cell lung cancers, have been extensively investigated. Somatostatin has been used in the clinical setting for the diagnosis of acromegaly and gastrointestinal tract tumours. Its analogues have been developed to achieve more favourable kinetics for efficiency use in the management of acute conditions, such as esophageal varices. Octreotide is a long-acting analogue of somatostatin that inhibits the release of a number of hormones, and is clinically used to relieve symptoms of uncommon gastroenteropancreatic endocrine tumours, as well as treat acromegaly.",6E20216Q0L,38916-34-6,"InChI=1S/C76H104N18O19S2/c1-41(79)64(100)82-37-61(99)83-58-39-114-115-40-59(76(112)113)92-72(108)57(38-95)91-75(111)63(43(3)97)94-71(107)54(33-46-23-11-6-12-24-46)90-74(110)62(42(2)96)93-66(102)51(28-16-18-30-78)84-69(105)55(34-47-36-81-49-26-14-13-25-48(47)49)88-68(104)53(32-45-21-9-5-10-22-45)86-67(103)52(31-44-19-7-4-8-20-44)87-70(106)56(35-60(80)98)89-65(101)50(85-73(58)109)27-15-17-29-77/h4-14,19-26,36,41-43,50-59,62-63,81,95-97H,15-18,27-35,37-40,77-79H2,1-3H3,(H2,80,98)(H,82,100)(H,83,99)(H,84,105)(H,85,109)(H,86,103)(H,87,106)(H,88,104)(H,89,101)(H,90,110)(H,91,111)(H,92,108)(H,93,102)(H,94,107)(H,112,113)/t41-,42+,43+,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,62-,63-/m0/s1",NHXLMOGPVYXJNR-ATOGVRKGSA-N,C[C@@H](C(NCC(N[C@H]1CSSC[C@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC1=O)CCCCN)=O)CC(N)=O)=O)CC2=CC=CC=C2)=O)CC3=CC=CC=C3)=O)CC4=CNC5=CC=CC=C45)=O)CCCCN)=O)[C@H](O)C)=O)CC6=CC=CC=C6)=O)[C@H](O)C)=O)CO)=O)C(O)=O)=O)=O)N,"Various tumours, Oesophageal varices haemorrhage, Gastritis haemorrhagic, Acromegaly","For the symptomatic treatment of acute bleeding from esophageal varices, gastrointestinal ulcers, and gastritis; prevent pancreatic complications after surgery; and restrict secretions of the upper intestine, pancreas, and biliary tract. Somatostatin have been extensively investigated for use/treatment in various tumours, including pituitary adenomas, GEP-NETs, paragangliomas, carcinoids, breast cancers, malignant lymphoma and small-cell lung cancers."
DCTPepD0015,Sovateltide,16133819,DB06138,C74027,SPI-1620; IRL-1620; Endothelin B Receptor Agonist SPI-1620; Sovateltide; PMZ-1620,DEEAVYFAHLDIIW,14,C-terminal Suc,C86H117N17O27,1820.9,N-(3-carboxypropanoyl)-L-alpha-aspartyl-L-alpha-glutamyl-L-alpha-glutamyl-L-alanyl-L-valyl-L-tyrosyl-L-phenylalanyl-L-alanyl-L-histidyl-L-leucyl-L-alpha-aspartyl-L-isoleucyl-L-isoleucyl-L-tryptophan,Endothelin-B receptor agonist##Peptide and derivative,Small Molecule,"A highly selective peptide agonist of the endothelin-B receptor. Sovateltide binds to endothelin-B receptors on endothelial cells in tumor blood vessels, which, unlike the angioarchitecture of normal blood vessels, are relatively devoid of smooth muscle. This agent may induce a transient, selective increase in blood flow to a tumor, which may result in an increase in the delivery of anticancer agents to the tumor and, so, an increase in anticancer agent efficacy.",11X778QIZS,142569-99-1,"InChI=1S/C86H117N17O27/c1-11-44(7)71(84(127)100-63(86(129)130)35-50-39-88-54-21-17-16-20-53(50)54)103-85(128)72(45(8)12-2)102-82(125)62(38-69(114)115)98-78(121)57(32-42(3)4)96-80(123)60(36-51-40-87-41-89-51)95-73(116)46(9)91-77(120)58(33-48-18-14-13-15-19-48)97-79(122)59(34-49-22-24-52(104)25-23-49)99-83(126)70(43(5)6)101-74(117)47(10)90-75(118)55(26-29-65(106)107)93-76(119)56(27-30-66(108)109)94-81(124)61(37-68(112)113)92-64(105)28-31-67(110)111/h13-25,39-47,55-63,70-72,88,104H,11-12,26-38H2,1-10H3,(H,87,89)(H,90,118)(H,91,120)(H,92,105)(H,93,119)(H,94,124)(H,95,116)(H,96,123)(H,97,122)(H,98,121)(H,99,126)(H,100,127)(H,101,117)(H,102,125)(H,103,128)(H,106,107)(H,108,109)(H,110,111)(H,112,113)(H,114,115)(H,129,130)/t44-,45-,46-,47-,55-,56-,57-,58-,59-,60-,61-,62-,63-,70-,71-,72-/m0/s1",DXPHNGAMYPPTBJ-TZMIJSMNSA-N,CC[C@@H]([C@@H](C(N[C@@H]([C@H](CC)C)C(N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12)=O)=O)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](C(C)C)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CCC(O)=O)=O)CC(O)=O)=O)CCC(O)=O)=O)CCC(O)=O)=O)C)=O)=O)CC3=CC=C(C=C3)O)=O)CC4=CC=CC=C4)=O)C)=O)CC5=CNC=N5)=O)CC(C)C)=O)CC(O)=O)=O)C,Cancer/Tumor,Investigated for use/treatment in cancer/tumors (unspecified).
DCTPepD0016,SF1126,92043140,DB05210,C85469,pan-PI3K/mTOR Inhibitor SF1126; SF1126,XRGDS,5,X=LY294002 (Small-molecule prodrug containing the pan-PI3K/mTOR inhibitor),C39H48N8O14,852.8,(3S)-4-[[(1S)-1-carboxy-2-hydroxyethyl]amino]-3-[[2-[[(2S)-5-(diaminomethylideneamino)-2-[[4-oxo-4-[[4-(4-oxo-8-phenylchromen-2-yl)morpholin-4-ium-4-yl]methoxy]butanoyl]amino]pentanoyl]amino]acetyl]amino]-4-oxobutanoate,pan-PI3K/mTOR Inhibitor##Peptide and derivative##Peptide-Drug Conjugates##Cancer Targeted Conjugates,Small Molecule,"A water soluble, small-molecule prodrug containing the pan-PI3K/mTOR inhibitor LY294002/SF1101 conjugated to the RGD-containing tetra-peptide SF1174 with potential antineoplastic and antiangiogenic activities. The targeting peptide SF1174 moiety of pan-PI3K/mTOR inhibitor SF1126 selectively binds to cell surface integrins and, upon cell entry, the agent is hydrolyzed to the active drug SF1101; SF1101 selectively inhibits all isoforms of phosphoinositide-3-kinase (PI3K) and other members of the PI3K superfamily, such as the mammalian target of rapamycin (mTOR) and DNA-PK. By inhibiting the PI3K signaling pathway, this agent may inhibit tumor cell and tumor endothelial cell proliferation and survival.",DL0Q912033,936487-67-1,"InChI=1S/C39H48N8O14/c40-39(41)42-13-5-10-26(36(55)43-20-31(51)45-27(18-33(52)53)37(56)46-28(21-48)38(57)58)44-30(50)11-12-34(54)60-22-47(14-16-59-17-15-47)32-19-29(49)25-9-4-8-24(35(25)61-32)23-6-2-1-3-7-23/h1-4,6-9,19,26-28,48H,5,10-18,20-22H2,(H9-,40,41,42,43,44,45,46,50,51,52,53,55,56,57,58)/t26-,27-,28-/m0/s1",SVNJBEMPMKWDCO-KCHLEUMXSA-N,O=C([O-])C[C@H](NC(CNC([C@@H](NC(CCC(OC[N+]1(C2=CC(C3=C(O2)C(C4=CC=CC=C4)=CC=C3)=O)CCOCC1)=O)=O)CCC/N=C(N)\N)=O)=O)C(N[C@H](C(O)=O)CO)=O,Various forms of cancer,For the treatment of various forms of cancer.
DCTPepD0019,Leuprolide,657181,DB00007,C62042,Leuprorelin; 6-D-Leucine-9-(N-ethyl-L-prolinamide)-1-9-luteinizing Hormone-releasing Factor (Pig); 6-D-Leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide Luteinizing Hormone-Releasing Factor (Pig); Leuprolide,XHWSYLLRP,9,"X=Pyr, N-terminal NHEt",C59H84N16O12,1209.4,(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide,Peptide and derivative##Hormone and analogue,Small Molecule,"A synthetic nonapeptide analogue of gonadotropin-releasing hormone. Leuprolide binds to and activates gonadotropin-releasing hormone (GnRH) receptors. Continuous, prolonged administration of leuprolide in males results in pituitary GnRH receptor desensitization and inhibition of pituitary secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. This agent reduces testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression.",EFY6W0M8TG,53714-56-0,"InChI=1S/C59H84N16O12/c1-6-63-57(86)48-14-10-22-75(48)58(87)41(13-9-21-64-59(60)61)68-51(80)42(23-32(2)3)69-52(81)43(24-33(4)5)70-53(82)44(25-34-15-17-37(77)18-16-34)71-56(85)47(30-76)74-54(83)45(26-35-28-65-39-12-8-7-11-38(35)39)72-55(84)46(27-36-29-62-31-66-36)73-50(79)40-19-20-49(78)67-40/h7-8,11-12,15-18,28-29,31-33,40-48,65,76-77H,6,9-10,13-14,19-27,30H2,1-5H3,(H,62,66)(H,63,86)(H,67,78)(H,68,80)(H,69,81)(H,70,82)(H,71,85)(H,72,84)(H,73,79)(H,74,83)(H4,60,61,64)/t40-,41-,42-,43+,44-,45-,46-,47-,48-/m0/s1",GFIJNRVAKGFPGQ-LIJARHBVSA-N,O=C([C@H](CC1)NC1=O)N[C@@H](CC2=CN=CN2)C(N[C@@H](CC3=CNC4=C3C=CC=C4)C(N[C@@H](CO)C(N[C@@H](CC5=CC=C(O)C=C5)C(N[C@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CCC/N=C(N)\N)C(N6[C@H](C(NCC)=O)CCC6)=O)=O)=O)=O)=O)=O)=O,"Advanced Prostate Cancer, Anemia, Central Precocious Puberty (CPP), Endometriosis","Leuprolide is indicated for the treatment of advanced prostate cancer and as palliative treatment of advanced prostate cancer.<br>It is also used for the treatment of pediatric patients with central precocious puberty (CPP).<br>In combination with oral norethisterone (also known as norethindrone), leuprolide is also indicated for the initial treatment of the symptoms of endometriosis. Finally, in combination with iron supplementation, leuprolide is indicated for the preoperative hematological improvement of anemic patients with uterine leiomyomata (uterine fibroids)."
DCTPepD0030,ADH-1,9916058,DB05485,C53399,Exherin; ADH-1,CHAVC,5,"C-terminal Ac, N-terminal NH2",C22H34N8O6S2,570.7,"(4R,7S,10S,13S,16R)-16-acetamido-13-(1H-imidazol-5-ylmethyl)-10-methyl-6,9,12,15-tetraoxo-7-propan-2-yl-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide",Peptide and derivative##Cyclic##Antiangiogenesis agent,Biotech,"A small, cyclic pentapeptide vascular-targeting agent with potential antineoplastic and antiangiogenic activities. ADH-1 selectively and competitively binds to and blocks N-cadherin, which may result in disruption of tumor vasculature, inhibition of tumor cell growth, and the induction of tumor cell and endothelial cell apoptosis. N-cadherin, a cell- surface transmembrane glycoprotein of the cadherin superfamily of proteins involved in calcium-mediated cell-cell adhesion and signaling mechanisms; may be upregulated in some aggressive tumors and the endothelial cells and pericytes of some tumor blood vessels.",B058ME29VU,229971-81-7,"InChI=1S/C22H34N8O6S2/c1-10(2)17-22(36)29-15(18(23)32)7-37-38-8-16(27-12(4)31)21(35)28-14(5-13-6-24-9-25-13)20(34)26-11(3)19(33)30-17/h6,9-11,14-17H,5,7-8H2,1-4H3,(H2,23,32)(H,24,25)(H,26,34)(H,27,31)(H,28,35)(H,29,36)(H,30,33)/t11-,14-,15-,16-,17-/m0/s1",FQVLRGLGWNWPSS-BXBUPLCLSA-N,O=C(C)N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N1)=O)C(C)C)=O)C)=O)CC2=CN=CN2)=O)CSSC[C@H]1C(N)=O,Cancer/Tumor,"Investigated for use/treatment in breast cancer, cancer/tumors (unspecified), melanoma, ovarian cancer, and solid tumors."
DCTPepD0031,ATN-161,9960285,DB05491,C52185,α5β1 Inhibitor ATN-161; ATN-161,PHSCN,5,"C-terminal Ac, N-terminal NH2",C23H35N9O8S,597.6,(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-acetylpyrrolidine-2-carbonyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-sulfanylpropanoyl]amino]butanediamide,Integrin α5β1 antagonist##Peptide and derivative##Antiangiogenesis agent,Small Molecule,"A small peptide antagonist of integrin alpha5beta1 with potential antineoplastic activity. ATN-161 selectively binds to and blocks the receptor for integrin alpha5beta1, thereby preventing integrin alpha5beta1 binding. This receptor blockade may result in inhibition of endothelial cell-cell interactions, endothelial cell-matrix interactions, angiogenesis, and tumor progression. Integrin alpha5beta1 is expressed on endothelial cells and plays a crucial role in endothelial cell adhesion and migration. ATN-161 may prevent the spread of tumor cells and may prevent the growth of new blood vessels that tumors need to grow. It is a type of antiangiogenesis agent.",XW0H5LE42K,262438-43-7,"InChI=1S/C23H35N9O8S/c1-11(34)32-4-2-3-17(32)23(40)29-14(5-12-7-26-10-27-12)20(37)30-15(8-33)21(38)31-16(9-41)22(39)28-13(19(25)36)6-18(24)35/h7,10,13-17,33,41H,2-6,8-9H2,1H3,(H2,24,35)(H2,25,36)(H,26,27)(H,28,39)(H,29,40)(H,30,37)(H,31,38)/t13-,14-,15-,16-,17-/m0/s1",MMHDBUJXLOFTLC-WOYTXXSLSA-N,O=C(N)[C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H]1N(C(C)=O)CCC1)=O)CC2=CN=CN2)=O)CO)=O)CS)=O)CC(N)=O,Cancer/Tumor,Investigated for use/treatment in brain cancer and cancer/tumors (unspecified).
DCTPepD0033,CTCE-9908,16186350,DB05625,C170746,SDF-1 Receptor Antagonist PTX-9908; CXCR4 Antagonist CTCE-9908; PTX 9908; PTX-9908; SDF-1 Analog PTX-9908; CTCE-9908,KGVSLSYRXRYSLSVGK,17,X=Lys-NH2,C86H147N27O23,1927.3,"(2S)-2,6-diamino-N-[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(5S)-6-amino-5-[[(2S)-5-carbamimidamido-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2,6-diaminohexanoyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]pentanoyl]amino]-6-oxohexyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-2-oxoethyl]hexanamide",CXCR4 antagonist##Peptide and derivative,Small Molecule,"A stromal cell-derived factor 1 (SDF-1; CXCL12) analog and inhibitor of C-X-C chemokine receptor type 4 (CXCR4), with potential antineoplastic activity. Upon administration, PTX-9908 selectively targets and binds to CXCR4, thereby preventing the binding of CXCR4 to its ligand SDF-1. This inhibits receptor activation and results in decreased proliferation and migration of CXCR4-overexpressing tumor cells. The G protein-coupled receptor CXCR4, which is overexpressed in several tumor cell types, promotes tumor angiogenesis, tumor cell proliferation, survival, invasion and metastasis. SDF-1, a major chemotactic factor, plays a key role in mediating cell trafficking via selective binding to CXCR4.",NF0BX95A31,1030384-98-5,"InChI=1S/C86H147N27O23/c1-45(2)35-58(104-81(133)64(43-116)110-83(135)68(47(5)6)112-66(120)39-99-71(123)53(89)17-9-12-30-87)75(127)108-62(41-114)79(131)106-60(37-49-22-26-51(118)27-23-49)77(129)102-56(20-15-33-97-85(92)93)73(125)96-32-14-11-19-55(70(91)122)101-74(126)57(21-16-34-98-86(94)95)103-78(130)61(38-50-24-28-52(119)29-25-50)107-80(132)63(42-115)109-76(128)59(36-46(3)4)105-82(134)65(44-117)111-84(136)69(48(7)8)113-67(121)40-100-72(124)54(90)18-10-13-31-88/h22-29,45-48,53-65,68-69,114-119H,9-21,30-44,87-90H2,1-8H3,(H2,91,122)(H,96,125)(H,99,123)(H,100,124)(H,101,126)(H,102,129)(H,103,130)(H,104,133)(H,105,134)(H,106,131)(H,107,132)(H,108,127)(H,109,128)(H,110,135)(H,111,136)(H,112,120)(H,113,121)(H4,92,93,97)(H4,94,95,98)/t53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,68-,69-/m0/s1",VUYRSKROGTWHDC-HZGLMRDYSA-N,OC(C=C1)=CC=C1C[C@H](NC([C@H](CO)NC([C@H](CC(C)C)NC([C@H](CO)NC([C@H](C(C)C)NC(CNC([C@@H](N)CCCCN)=O)=O)=O)=O)=O)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@H](C(N)=O)CCCCNC([C@H](CCCNC(N)=N)NC([C@@H](NC([C@H](CO)NC([C@H](CC(C)C)NC([C@H](CO)NC([C@H](C(C)C)NC(CNC([C@@H](N)CCCCN)=O)=O)=O)=O)=O)=O)CC2=CC=C(O)C=C2)=O)=O)=O)=O,Cancer/Tumor,"Investigated for use/treatment in cancer/tumors (unspecified), lung cancer, and sarcoma."
DCTPepD0034,Darinaparsin,11683005,DB06179,C61490,DMAIII(SG); S-Dimethylarsino-Glutathione; ZIO-101; Darinaparsin,XXG,3,"X(1)=gGlu, X(2)=Cys(Unk)",C12H22AsN3O6S,411.31,(2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-3-dimethylarsanylsulfanyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid,Peptide and derivative,Small Molecule,"A small-molecule organic arsenical with potential antineoplastic activity. Although the exact mechanism of action is unclear, darinaparsin, a highly toxic metabolic intermediate of inorganic arsenicals (iAs) that occurs in vivo, appears to generate volatile cytotoxic arsenic compounds when glutathione (GSH) concentrations are low. The arsenic compounds generated from darinaparsin disrupt mitochondrial bioenergetics, producing reactive oxygen species (ROS) and inducing ROS-mediated tumor cell apoptosis; in addition, this agent or its byproducts may initiate cell death by interrupting the G2/M phase of the cell cycle and may exhibit antiangiogenic effects. Compared to inorganic arsenic compounds such as arsenic trioxide (As2O3), darinaparsin appears to exhibit a wide therapeutic window.",9XX54M675G,69819-86-9,"InChI=1S/C12H22AsN3O6S/c1-13(2)23-6-8(11(20)15-5-10(18)19)16-9(17)4-3-7(14)12(21)22/h7-8H,3-6,14H2,1-2H3,(H,15,20)(H,16,17)(H,18,19)(H,21,22)/t7-,8-/m0/s1",JGDXFQORBMPJGR-YUMQZZPRSA-N,O=C(O)[C@@H](N)CCC(N[C@@H](CS[As](C)C)C(NCC(O)=O)=O)=O,Cancer/Tumor,"Investigated for use/treatment in blood (blood forming organ disorders, unspecified), cancer/tumors (unspecified), solid tumors, multiple myeloma, and liver cancer."
DCTPepD0037,Foxy-5,44628955,DB13034,C113435,Wnt-5a Mimic Hexapeptide Foxy-5; Foxy-5,MDGCEL,6,C-terminal HCO,C26H42N6O12S2,694.8,(2S)-2-[[(2S)-4-carboxy-2-[[(2R)-2-[[2-[[(2S)-3-carboxy-2-[[(2S)-2-formamido-4-methylsulfanylbutanoyl]amino]propanoyl]amino]acetyl]amino]-3-sulfanylpropanoyl]amino]butanoyl]amino]-4-methylpentanoic acid,Peptide and derivative,Small Molecule,"A formylated, six amino acid, Wnt5a-derived peptide and wnt-5a mimetic with potential anti-metastatic activity. Upon intravenous administration, Wnt-5a mimic hexapeptide foxy-5 binds to and activates the wnt-5a receptors, Frizzled-2 and -5, which activates wnt-5a-mediated signaling. Increased wnt-5a signaling may inhibit endothelial tumor cell migration and invasion. This may decrease metastasis of susceptible tumor cells. However, foxy-5 does not affect tumor cell proliferation or apoptosis. Foxy-5 lacks a heparan sulfate-binding domain and contains a formyl group on its NH2-terminal methionine residue which decreases in vivo degradation. Decreased expression of wnt-5a protein is associated with increased motility of certain tumor cell types.",CBZ9UL0ARB,881188-51-8,"InChI=1S/C26H42N6O12S2/c1-13(2)8-17(26(43)44)32-24(41)15(4-5-20(35)36)30-25(42)18(11-45)29-19(34)10-27-22(39)16(9-21(37)38)31-23(40)14(28-12-33)6-7-46-3/h12-18,45H,4-11H2,1-3H3,(H,27,39)(H,28,33)(H,29,34)(H,30,42)(H,31,40)(H,32,41)(H,35,36)(H,37,38)(H,43,44)/t14-,15-,16-,17-,18-/m0/s1",WFZPJYYCTSHDJI-ATIWLJMLSA-N,CC(C)C[C@H](NC([C@@H](NC([C@@H](NC(CNC([C@@H](NC([C@@H](NC=O)CCSC)=O)CC(O)=O)=O)=O)CS)=O)CCC(O)=O)=O)C(O)=O,"Prostate Cancer, Colorectal Cancer, Metastatic Colon Cancer, Metastatic Breast Cancer, Metastatic Prostate Cancer","Foxy-5 has been used in trials studying the treatment of Prostate Cancer, Colorectal Cancer, Metastatic Colon Cancer, Metastatic Breast Cancer, and Metastatic Prostate Cancer."
DCTPepD0038,LCL-161,24737642,DB12085,C91079,Smac Mimetic LCL161; LCL-161,AX,2,"X=Chg-Unk, C-terminal Me",C26H33FN4O3S,500.6,"(2S)-N-[(1S)-1-cyclohexyl-2-[(2S)-2-[4-(4-fluorobenzoyl)-1,3-thiazol-2-yl]pyrrolidin-1-yl]-2-oxoethyl]-2-(methylamino)propanamide",Inhibitor of IAP family of proteins##Peptide and derivative,Small Molecule,"An orally bioavailable second mitochondrial-derived activator of caspases (SMAC) mimetic and inhibitor of IAP (Inhibitor of Apoptosis Protein) family of proteins, with potential antineoplastic activity. SMAC mimetic LCL161 binds to IAPs, such as X chromosome-linked IAP (XIAP) and cellular IAPs 1 and 2. Since IAPs shield cancer cells from the apoptosis process, this agent may restore and promote the induction of apoptosis through apoptotic signaling pathways in cancer cells. IAPs are overexpressed by many cancer cell types and suppress apoptosis by binding and inhibiting active caspases-3, -7 and -9, which play essential roles in apoptosis (programmed cell death), necrosis and inflammation.",6TNS415Y3P,1005342-46-0,"InChI=1S/C26H33FN4O3S/c1-16(28-2)24(33)30-22(17-7-4-3-5-8-17)26(34)31-14-6-9-21(31)25-29-20(15-35-25)23(32)18-10-12-19(27)13-11-18/h10-13,15-17,21-22,28H,3-9,14H2,1-2H3,(H,30,33)/t16-,21-,22-/m0/s1",UFPFGVNKHCLJJO-SSKFGXFMSA-N,C[C@H](NC)C(N[C@@H](C1CCCCC1)C(N2[C@H](C3=NC(C(C4=CC=C(F)C=C4)=O)=CS3)CCC2)=O)=O,"Leukemia, Neoplasms, Solid Tumors, Breast Cancer, Ovarian Cancer","LCL161 has been used in trials studying the treatment of Leukemia, Neoplasms, Solid Tumors, Breast Cancer, and Ovarian Cancer, among others."
DCTPepD0040,Oglufanide,100094,DB05779,C76274,"Glu-trp; Glutamyltryptophan; L-Tryptophan, L-alpha-glutamyl-; Thymogen; Oglufanide",EW,2,Not available,C16H19N3O5,333.34,(4S)-4-amino-5-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-5-oxopentanoic acid,Immunomodulator##Peptide and derivative,Small Molecule,"Glu-Trp is a dipeptide composed of L-glutamic acid and L-tryptophan joined by a peptide linkage. It has a role as a metabolite, an immunomodulator, an angiogenesis modulating agent and an antineoplastic agent. It is functionally related to a L-glutamic acid and a L-tryptophan.",4RHY598T5U,38101-59-6,"InChI=1S/C16H19N3O5/c17-11(5-6-14(20)21)15(22)19-13(16(23)24)7-9-8-18-12-4-2-1-3-10(9)12/h1-4,8,11,13,18H,5-7,17H2,(H,19,22)(H,20,21)(H,23,24)/t11-,13-/m0/s1",LLEUXCDZPQOJMY-AAEUAGOBSA-N,O=C(O)CC[C@H](N)C(N[C@H](C(O)=O)CC1=CNC2=C1C=CC=C2)=O,"Colorectal Cancer, Ovarian Cancer, Kaposi's Sarcoma","Investigated for use/treatment in hepatitis (viral, C) and cancer."
DCTPepD0041,Tigapotide,16155604,DB04985,C78474,PCK3145; Prostate-Secretory Protein-94-Derived Peptide PCK3145; Tigapotide,EWQTDNXETXTXYET,15,X=Cys(ACM),C82H119N21O34S3,2039.1,"(4S)-5-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2R)-3-(acetamidomethylsulfanyl)-1-[[(2S)-1-[[(2S,3R)-1-[[(2R)-3-(acetamidomethylsulfanyl)-1-[[(2S,3R)-1-[[(2R)-3-(acetamidomethylsulfanyl)-1-[[(2S)-1-[[(2S)-4-carboxy-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-amino-1,4-dioxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-amino-1,5-dioxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-amino-5-oxopentanoic acid",Peptide and derivative##Antiangiogenesis agent,Biotech,"A synthetic 15-mer peptide corresponding to amino acids 31-45 of the 94-amino acid isoform of human prostate secretory protein (PSP-94) with potential anti-metastasis and anti-angiogenesis activities. PSP-94-derived peptide PCK3145 may inhibit the secretion of the metastasis-related protein matrix metalloproteinase-9 (MMP-9) and its potential binding to its cell surface receptor CD44; may interfere with the vascular endothelial growth factor (VEGF) signaling pathway, resulting in an anti-angiogenesis effect; and may reduce the levels of parathyroid hormone-related protein (PTHrP), decreasing plasma calcium levels. PSP-94, one of three predominant proteins found in seminal fluid, may be down-regulated in prostate cancer, representing a potential survival mechanism for prostate cancer cells. MMP-9 is implicated in the invasion and metastasis of cancer. PTHrP may be expressed by various tumor cell types, resulting in the hypercalcemia of malignancy.",1WZ6S45S94,848084-83-3,"InChI=1S/C82H119N21O34S3/c1-35(104)64(100-69(123)48(17-20-58(84)112)90-73(127)52(93-68(122)46(83)16-21-60(114)115)25-43-28-86-47-11-9-8-10-45(43)47)79(133)96-54(27-63(120)121)75(129)95-53(26-59(85)113)74(128)97-55(29-138-32-87-39(5)108)76(130)92-49(18-22-61(116)117)70(124)101-65(36(2)105)80(134)99-57(31-140-34-89-41(7)110)78(132)102-66(37(3)106)81(135)98-56(30-139-33-88-40(6)109)77(131)94-51(24-42-12-14-44(111)15-13-42)72(126)91-50(19-23-62(118)119)71(125)103-67(38(4)107)82(136)137/h8-15,28,35-38,46,48-57,64-67,86,104-107,111H,16-27,29-34,83H2,1-7H3,(H2,84,112)(H2,85,113)(H,87,108)(H,88,109)(H,89,110)(H,90,127)(H,91,126)(H,92,130)(H,93,122)(H,94,131)(H,95,129)(H,96,133)(H,97,128)(H,98,135)(H,99,134)(H,100,123)(H,101,124)(H,102,132)(H,103,125)(H,114,115)(H,116,117)(H,118,119)(H,120,121)(H,136,137)/t35-,36-,37-,38-,46+,48+,49+,50+,51+,52+,53+,54+,55+,56+,57+,64+,65+,66+,67+/m1/s1",ZRXXHPDJLAQCPC-SFJRRRFZSA-N,O=C(O)CC[C@H](N)C(N[C@@H](CC1=CNC2=C1C=CC=C2)C(N[C@@H](CCC(N)=O)C(N[C@@H]([C@H](O)C)C(N[C@@H](CC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](CSCNC(C)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H]([C@H](O)C)C(N[C@@H](CSCNC(C)=O)C(N[C@@H]([C@H](O)C)C(N[C@@H](CSCNC(C)=O)C(N[C@@H](CC3=CC=C(O)C=C3)C(N[C@@H](CCC(O)=O)C(N[C@H](C(O)=O)[C@H](O)C)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O,Hormone Refractory Prostate Cancer (HRPC),For the treatment of late stage Hormone Refractory Prostate Cancer (HRPC) for which no effective therapy currently exists.
DCTPepD0044,SOR-C13,121596688,DB15366,C101525,TRPV6 Calcium Channel Inhibitor SOR-C13; SOR-C13,KEFLHPSKVDLPR,13,None,C72H116N20O19,1565.8,"(4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[(2S)-2-[[(1S)-1-carboxy-4-(diaminomethylideneamino)butyl]carbamoyl]pyrrolidin-1-yl]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-[[(2S)-2,6-diaminohexanoyl]amino]-5-oxopentanoic acid",TRPV6 Calcium Channel Inhibitor##Peptide and derivative,Small Molecule,"An inhibitor of transient receptor potential cation channel vanilloid family member 6 (TRPV6, CaT1 or CATL) with potential antineoplastic activity. TRPV6 calcium channel inhibitor SOR-C13 binds to TRPV6 and prevents the influx of calcium ions into TRPV6-expressing tumor cells. This inhibits the activation of nuclear factor of activated T-cell (NFAT) transcription complex which may result in an inhibition of calcium-dependent cancer cell proliferation and an induction of apoptosis in tumor cells overexpressing TRPV6. The TRPV6 ion channel plays a key role in calcium homeostasis and is highly selective for calcium compared to other cations; it is overexpressed in a variety of tumors and initiates tumor cell growth, proliferation and metastases.",C79B5A73C4,1187852-48-7,"InChI=1S/C72H116N20O19/c1-39(2)31-48(84-63(102)49(33-42-17-8-7-9-18-42)85-60(99)46(24-25-56(94)95)81-59(98)44(75)19-10-12-26-73)62(101)88-52(34-43-36-78-38-80-43)70(109)92-30-16-23-55(92)67(106)89-53(37-93)65(104)82-45(20-11-13-27-74)61(100)90-58(41(5)6)68(107)86-50(35-57(96)97)64(103)87-51(32-40(3)4)69(108)91-29-15-22-54(91)66(105)83-47(71(110)111)21-14-28-79-72(76)77/h7-9,17-18,36,38-41,44-55,58,93H,10-16,19-35,37,73-75H2,1-6H3,(H,78,80)(H,81,98)(H,82,104)(H,83,105)(H,84,102)(H,85,99)(H,86,107)(H,87,103)(H,88,101)(H,89,106)(H,90,100)(H,94,95)(H,96,97)(H,110,111)(H4,76,77,79)/t44-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,58-/m0/s1",LGANPTNILMNMES-TVNHODDRSA-N,OC(C[C@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H]1CCCN1C([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](N)CCCCN)=O)CCC(O)=O)=O)CC2=CC=CC=C2)=O)CC(C)C)=O)CC3=CN=CN3)=O)=O)CO)=O)CCCCN)=O)C(C)C)=O)C(N[C@H](C(N4CCC[C@H]4C(N[C@@H](CCCNC(N)=N)C(O)=O)=O)=O)CC(C)C)=O)=O,Advanced Cancers,Investigated for use/treatment in advanced cancers.
DCTPepD0053,Cilengitide,176873,DB11890,C1834,cyclo(L-arginylglycyl-L-a-aspartyl-D-phenylalanyl-N-methyl-L-valyl); EMD 121974; EMD-121974; Cilengitide,RGDFX,5,X=N(Me)Val,C27H40N8O7,588.7,"2-[(2S,5R,8S,11S)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-7-methyl-3,6,9,12,15-pentaoxo-8-propan-2-yl-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid",Integrin αvβ3/αvβ5 inhibitor##Peptide and derivative##Cyclic##Antiangiogenesis agent,Small Molecule,"A cyclic Arg-Gly-Asp peptide with potential antineoplastic activity. Cilengitide binds to and inhibits the activities of the alpha(v)beta(3) and alpha(v)beta(5) integrins, thereby inhibiting endothelial cell-cell interactions, endothelial cell-matrix interactions, and angiogenesis.",4EDF46E4GI,188968-51-6,"InChI=1S/C27H40N8O7/c1-15(2)22-25(41)33-17(10-7-11-30-27(28)29)23(39)31-14-20(36)32-18(13-21(37)38)24(40)34-19(26(42)35(22)3)12-16-8-5-4-6-9-16/h4-6,8-9,15,17-19,22H,7,10-14H2,1-3H3,(H,31,39)(H,32,36)(H,33,41)(H,34,40)(H,37,38)(H4,28,29,30)/t17-,18-,19+,22-/m0/s1",AMLYAMJWYAIXIA-VWNVYAMZSA-N,O=C(O)C[C@@H](C(N[C@H](CC1=CC=CC=C1)C(N(C)[C@@H](C(C)C)C(N[C@@H](CCC/N=C(N)\N)C(NC2)=O)=O)=O)=O)NC2=O,"Sarcoma, Gliomas, Lymphoma, Leukemia, Lung Cancer","Cilengitide has been used in trials studying the treatment of Sarcoma, Gliomas, Lymphoma, Leukemia, and Lung Cancer, among others."
DCTPepD0060,Vapreotide,71306,DB04894,C1429,BMY-41606; Docrised; RC-160; Vapreotide,FCYWKVCW,8,N-terminal NH2,C57H70N12O9S2,1131.4,"10-(4-aminobutyl)-N-[1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-19-[(2-amino-3-phenylpropanoyl)amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide",Somatostatin analogs##Peptide and derivative##Cyclic##Hormone and analogue,Small Molecule,"A synthetic cyclic octapeptide analogue of somatostatin with direct and indirect antitumor effects. Vapreotide binds to somatostatin receptors (SSTR), specifically SSTR-2 and to SSTR-5 with a lesser affinity, in the similar behaviors as other octapeptide somatostatin analogues. Like octreotide, this agent has direct and indirect antitumor effects via inhibiting the release of growth hormone and other peptides that regulate release of insulin, gastrointestinal hormones. Furthermore, vapreotide may also be useful for inducing hemostasis in cases of acute hemorrhage of the upper gastrointestinal tract.",2PK59M9GFF,103222-11-3,"InChI=1S/C57H70N12O9S2/c1-32(2)49-57(78)68-48(55(76)64-44(50(60)71)26-35-28-61-41-16-8-6-14-38(35)41)31-80-79-30-47(67-51(72)40(59)24-33-12-4-3-5-13-33)56(77)65-45(25-34-19-21-37(70)22-20-34)53(74)66-46(27-36-29-62-42-17-9-7-15-39(36)42)54(75)63-43(52(73)69-49)18-10-11-23-58/h3-9,12-17,19-22,28-29,32,40,43-49,61-62,70H,10-11,18,23-27,30-31,58-59H2,1-2H3,(H2,60,71)(H,63,75)(H,64,76)(H,65,77)(H,66,74)(H,67,72)(H,68,78)(H,69,73)/t40-,43+,44+,45+,46-,47+,48+,49+/m1/s1",SWXOGPJRIDTIRL-DOUNNPEJSA-N,CC([C@@H]1NC([C@@H](NC([C@H](NC([C@@H](NC([C@H](CSSC[C@H](NC1=O)C(N[C@H](C(N)=O)CC2=CNC3=CC=CC=C23)=O)NC([C@@H](CC4=CC=CC=C4)N)=O)=O)CC5=CC=C(C=C5)O)=O)CC6=CNC7=CC=CC=C67)=O)CCCCN)=O)C,Pancreatic Cancer,For the treatment of esophageal variceal bleeding in patients with cirrhotic liver disease and has also shown efficacy in the treatment of patients with AIDS-related diarrhea. It was being studied for the treatment of cancer.
DCTPepD0064,Corticorelin,16186200,DB05394,C394,Recombinant Human Corticotropin Releasing Factor; Therapeutic Corticotropin-Releasing Factor; CFR; Corticoliberin,SEEPPISLDLTFHLLREVLEMARAEQLAQQAHSNRKLMEII,41,None,C208H344N60O63S2,4757,Not available,Peptide and derivative,Biotech,"Any synthetic therapeutic agent which is chemically identical to or similar to the endogenous human corticotropin-releasing factor (hCRF). Synthesized in the hypothalamus, hCRF stimulates the anterior pituitary gland to secrete adrenocorticotropic hormone (ACTH). In cerebral edema, hCRF acts by impeding the flow of fluid from blood vessels into brain tissue, thereby decreasing edema and stabilizing intracranial pressure. This agent possesses anti-edema properties independent of adrenal gland function.",305OE8862Y,86784-80-7,Not available,Not available,Not available,Brain cancer,Investigated for use/treatment in brain cancer and neurologic disorders.
DCTPepD0066,Iseganan,16131103,DB16010,C174882,Antimicrobial peptide IB-367; IB 367; IB367; IB-367; Iseganan,RGGLCYCRGRFCVCVGR,17,N-terminal NH2,C78H126N30O18S4,1900.3,"(1R,4S,7R,12R,15S,18R,21S,24S,30S)-N-[(2S)-1-[[2-[[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]-7-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-5-carbamimidamidopentanoyl]amino]acetyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-21-benzyl-24,30-bis(3-carbamimidamidopropyl)-4-[(4-hydroxyphenyl)methyl]-3,6,14,17,20,23,26,29,32-nonaoxo-15-propan-2-yl-9,10,34,35-tetrathia-2,5,13,16,19,22,25,28,31-nonazabicyclo[16.14.4]hexatriacontane-12-carboxamide",Peptide and derivative##Cyclic,Biotech,"A protegrin analogue containing 17 amino acids, which is effective for oral microorganisms.",Q9SAI36COS,257277-05-7,"InChI=1S/C78H126N30O18S4/c1-39(2)28-49(99-57(111)32-93-56(110)31-94-63(115)45(79)16-10-24-89-75(81)82)66(118)103-53-36-128-130-38-55(72(124)107-60(40(3)4)73(125)96-34-58(112)97-46(62(80)114)17-11-25-90-76(83)84)106-74(126)61(41(5)6)108-71(123)54-37-129-127-35-52(104-68(120)51(102-70(53)122)30-43-20-22-44(109)23-21-43)69(121)100-47(18-12-26-91-77(85)86)64(116)95-33-59(113)98-48(19-13-27-92-78(87)88)65(117)101-50(67(119)105-54)29-42-14-8-7-9-15-42/h7-9,14-15,20-23,39-41,45-55,60-61,109H,10-13,16-19,24-38,79H2,1-6H3,(H2,80,114)(H,93,110)(H,94,115)(H,95,116)(H,96,125)(H,97,112)(H,98,113)(H,99,111)(H,100,121)(H,101,117)(H,102,122)(H,103,118)(H,104,120)(H,105,119)(H,106,126)(H,107,124)(H,108,123)(H4,81,82,89)(H4,83,84,90)(H4,85,86,91)(H4,87,88,92)/t45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,60-,61-/m0/s1",GUCYBPFJNGVFEB-XELKFLSISA-N,CC(C[C@@H](C(N[C@H]1CSSC[C@H](NC([C@@H](NC([C@@H]2CSSC[C@@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N2)=O)CC3=CC=CC=C3)=O)CCCNC(N)=N)=O)=O)CCCNC(N)=N)=O)NC([C@@H](NC1=O)CC4=CC=C(C=C4)O)=O)=O)C(C)C)=O)C(N[C@@H](C(C)C)C(NCC(N[C@H](C(N)=O)CCCNC(N)=N)=O)=O)=O)=O)NC(CNC(CNC([C@H](CCCNC(N)=N)N)=O)=O)=O)C,Head and Neck Cancer,Investigated for use/treatment in Head and Neck Cancer.
DCTPepD0068,Lenomorelin,91668172,DB11895,C170105,Ghrelin; Ghrelin human; Human acylated ghrelin; Ghrelin (human); Lenomorelin,GXSFLSPEHQRVQQRKESKKPPAKLQPR,28,X=Ser(octanoyl),C149H249N47O42,3370.9,Not available,Peptide and derivative##Hormone and analogue,Biotech,"A 28 amino acid peptide hormone that was originally isolated from the stomach as the endogenous ligand for the growth hormone secretagogue receptor (GHSR). Ghrelin and its receptor are expressed in a number of cancers and cancer cell lines and may play a role in processes associated with cancer progression, including cell proliferation, apoptosis, and cell invasion and migration.",UXG268Q86R,258279-04-8,Not available,Not available,Not available,Cancer,"Lenomorelin has been investigated for the treatment and basic science of Cancer, Alcoholism, Metabolism, Hypopituitarism, and Frailty Syndrome, among others."
DCTPepD0069,Mipsagargin,24772106,DB11813,C90554,G-202; Mipsagargin,XXXXE,5,"X(1)=Asn(Unk), X(2/3/4)=gGlu",C66H100N6O27,1409.5,"(2S)-2-[[(4S)-4-[[(4S)-4-[[(4S)-4-[[(2S)-4-[[12-[[(3S,3aR,4S,6S,6aR,7S,8S,9bS)-6-acetyloxy-3,3a-dihydroxy-3,6,9-trimethyl-8-[(Z)-2-methylbut-2-enoyl]oxy-7-octanoyloxy-2-oxo-4,5,6a,7,8,9b-hexahydroazuleno[4,5-b]furan-4-yl]oxy]-12-oxododecyl]amino]-2-amino-4-oxobutanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]pentanedioic acid",Peptide and derivative,Small Molecule,"A soluble, thapsigargin prodrug containing the cytotoxic analog of thapsigargin, 8-O-(12Aminododecanoyl)-8-O debutanoylthapsigargin (12-ADT) linked, via a carboxyl group, to the targeting peptide containing aspartic acid with potential antineoplastic activity. Upon intravenous administration, mipsagargin targets prostate specific membrane antigen (PSMA), a type II membrane carboxypeptidase, which is overexpressed in prostate cancer cells and in the neovasculature of most solid tumors but not in normal blood vessels. Mipsagargin is subsequently converted, through hydrolysis, into the active cytotoxic analog of thapsigargin 12-ADT-Asp. 12-ADT binds to and blocks the Sarcoplasmic/Endoplasmic Reticulum Calcium ATPase (SERCA) pump, thereby increasing the concentration of cytosolic calcium which leads to an induction of apoptosis. By preventing nutrient supply to tumor cells, G-202 may be able to inhibit tumor growth. Compared to thapsigargin alone, thapsigargin prodrug G-202 is able to achieve higher concentrations of the active agents at the tumor site while avoiding systemic toxicity.",Q032I35QMX,1245732-48-2,"InChI=1S/C66H100N6O27/c1-8-10-11-17-20-24-51(81)96-55-53-52(37(4)54(55)97-62(91)36(3)9-2)56-66(94,65(7,93)63(92)98-56)44(35-64(53,6)99-38(5)73)95-50(80)23-21-18-15-13-12-14-16-19-22-33-68-48(77)34-39(67)57(82)72-43(61(89)90)27-31-47(76)70-41(59(85)86)25-29-45(74)69-40(58(83)84)26-30-46(75)71-42(60(87)88)28-32-49(78)79/h9,39-44,53-56,93-94H,8,10-35,67H2,1-7H3,(H,68,77)(H,69,74)(H,70,76)(H,71,75)(H,72,82)(H,78,79)(H,83,84)(H,85,86)(H,87,88)(H,89,90)/b36-9-/t39-,40-,41-,42-,43-,44-,53+,54-,55-,56-,64-,65+,66+/m0/s1",UPYNTAIBQVNPIH-ODMLWHIESA-N,C/C=C(C(O[C@H]1C(C)=C2[C@@H]3OC([C@@](O)([C@@]([C@H](C[C@](OC(C)=O)([C@H]2[C@@H]1OC(CCCCCCC)=O)C)OC(CCCCCCCCCCCNC(C[C@@H](C(N[C@H](C(O)=O)CCC(N[C@H](C(O)=O)CCC(N[C@H](C(O)=O)CCC(N[C@H](C(O)=O)CCC(O)=O)=O)=O)=O)=O)N)=O)=O)3O)C)=O)=O)/C,"Prostate Cancer, Advanced Solid Tumors, Glioblastoma Multiforme, Hepatocellular Carcinoma","Mipsagargin has been used in trials studying the treatment of Prostate Cancer, Prostatic Neoplasms, Advanced Solid Tumors, Glioblastoma Multiforme, and Hepatocellular Carcinoma, among others."
DCTPepD0078,Bombesin,16201612,DB11724,C315,Bombesin,XQRLGNQWAVGHLM,14,"X=Pyr, N-terminal NH2",C71H110N24O18S,1619.9,(2S)-2-[(2S)-2-{2-[(2S)-2-[(2S)-5-carbamimidamido-2-[(2S)-4-carbamoyl-2-{[(2S)-5-oxopyrrolidin-2-yl]formamido}butanamido]pentanamido]-4-methylpentanamido]acetamido}-3-carbamoylpropanamido]-N-[(1S)-1-{[(1S)-1-{[(1S)-1-[({[(1S)-1-{[(1S)-1-{[(1S)-1-carbamoyl-3-(methylsulfanyl)propyl]carbamoyl}-3-methylbutyl]carbamoyl}-2-(1H-imidazol-4-yl)ethyl]carbamoyl}methyl)carbamoyl]-2-methylpropyl]carbamoyl}ethyl]carbamoyl}-2-(1H-indol-3-yl)ethyl]pentanediamide,Peptide and derivative,Small Molecule,"A tetradecapeptide originally obtained from the skins of toads Bombina bombina and B. variegata. It is also an endogenous neurotransmitter in many animals including mammals. Bombesin affects vascular and other smooth muscle, gastric secretion, and renal circulation and function.",PX9AZU7QPK,31362-50-2 ,"InChI=1S/C71H110N24O18S/c1-34(2)24-47(92-62(105)43(14-11-22-79-71(76)77)89-64(107)45(15-18-52(72)96)90-63(106)44-17-20-55(99)85-44)61(104)81-31-56(100)87-51(28-54(74)98)69(112)91-46(16-19-53(73)97)65(108)94-49(26-38-29-80-41-13-10-9-12-40(38)41)66(109)84-37(7)60(103)95-58(36(5)6)70(113)82-32-57(101)86-50(27-39-30-78-33-83-39)68(111)93-48(25-35(3)4)67(110)88-42(59(75)102)21-23-114-8/h9-10,12-13,29-30,33-37,42-51,58,80H,11,14-28,31-32H2,1-8H3,(H2,72,96)(H2,73,97)(H2,74,98)(H2,75,102)(H,78,83)(H,81,104)(H,82,113)(H,84,109)(H,85,99)(H,86,101)(H,87,100)(H,88,110)(H,89,107)(H,90,106)(H,91,112)(H,92,105)(H,93,111)(H,94,108)(H,95,103)(H4,76,77,79)/t37-,42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,58-/m0/s1",QXZBMSIDSOZZHK-DOPDSADYSA-N,NC(CC[C@H](NC([C@@H](NC(CNC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](N1)CCC1=O)=O)CCC(N)=O)=O)CCCNC(N)=N)=O)CC(C)C)=O)=O)CC(N)=O)=O)C(N[C@H](C(N[C@@H](C)C(N[C@H](C(NCC(N[C@@H](CC2=CN=CN2)C(N[C@H](C(N[C@H](C(N)=O)CCSC)=O)CC(C)C)=O)=O)=O)C(C)C)=O)=O)CC3=CNC4=CC=CC=C43)=O)=O,Prostate Cancer,Investigated for use/treatment in Prostate Cancer.
DCTPepD0088,LTX-315,46200994,DB12748,C90547,Oncopore; Ruxotemitide; LTX-315,KKWWKKWXK,9,"X=Dip, N-terminal NH2",C78H106N18O9,1439.8,"(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2,6-diaminohexanamido]hexanamido]-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanamido]hexanamido]hexanamido]-3-(1H-indol-3-yl)propanamido]-3,3-diphenylpropanamido]hexanamide",Peptide and derivative,Small Molecule,"A peptide derived from human lactoferrin, with potential lytic and immunostimulating activities. Upon transdermal injection directly into the tumor, ruxotemitide may bind to the tumor cell membranes and subsequently lyse tumor cells, thereby inducing tumor cell necrosis. In turn, presentation of the tumor antigens to the immune system may induce systemic innate and adaptive immune responses mediated by anti-tumor natural killer (NK) cells, cytotoxic T lymphocytes, and natural killer T (NKT) cells. This may trigger an immune response against tumor associated antigens on tumors distant from the primary tumor. Human lactoferrin, a 692 amino acid glycoprotein, belongs to the transferrin family of metal-binding proteins.",75FBL12IZ7,1345407-05-7,"InChI=1S/C78H106N18O9/c79-38-18-13-30-57(84)71(98)90-62(35-15-20-40-81)73(100)93-66(44-52-47-87-59-32-11-8-28-55(52)59)76(103)95-65(43-51-46-86-58-31-10-7-27-54(51)58)75(102)92-63(36-16-21-41-82)72(99)91-64(37-17-22-42-83)74(101)94-67(45-53-48-88-60-33-12-9-29-56(53)60)77(104)96-69(78(105)89-61(70(85)97)34-14-19-39-80)68(49-23-3-1-4-24-49)50-25-5-2-6-26-50/h1-12,23-29,31-33,46-48,57,61-69,86-88H,13-22,30,34-45,79-84H2,(H2,85,97)(H,89,105)(H,90,98)(H,91,99)(H,92,102)(H,93,100)(H,94,101)(H,95,103)(H,96,104)/t57-,61-,62-,63-,64-,65-,66-,67-,69-/m0/s1",GGAKLYWEFZCVIT-TVEKFXMRSA-N,NCCCC[C@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](N)CCCCN)=O)CCCCN)=O)CC1=CNC2=C1C=CC=C2)=O)CC3=CNC4=CC=CC=C34)=O)C(N[C@@H](CCCCN)C(N[C@H](C(N[C@@H](C(C5=CC=CC=C5)C6=CC=CC=C6)C(N[C@H](C(N)=O)CCCCN)=O)=O)CC7=CNC8=C7C=CC=C8)=O)=O,"Lymphoma, Melanoma, Carcinoma, Breast Cancer","LTX-315 has been used in trials studying the treatment of Cancer, Lymphoma, Melanoma, Carcinoma, and Breast Cancer, among others."
DCTPepD0105,Tasidotin hydrochloride,11479259,Not available,C142999,ILX-651; Tasidotin HCl; Tasidotin Hydrochloride,VVXPP,5,"X=N(Me)Val, C-terminal Me2, N-terminal NHtBu.HCl",C32H59ClN6O5,643.3,(2S)-N-tert-butyl-1-[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide;hydrochloride,Peptide and derivative,Small Molecule,"A  synthetic analogue of dolastatin 15. Dolastatins are a group of structurally unique peptides originally isolated from a sea hare, Dolabella auricularia, which seem to inhibit tubulin polymerization and mitosis. ",3382C833Z5,623174-20-9 ,"InChI=1S/C32H58N6O5.ClH/c1-19(2)24(33-28(40)25(20(3)4)35(10)11)30(42)36(12)26(21(5)6)31(43)38-18-14-16-23(38)29(41)37-17-13-15-22(37)27(39)34-32(7,8)9;/h19-26H,13-18H2,1-12H3,(H,33,40)(H,34,39);1H/t22-,23-,24+,25-,26-;/m0./s1",OOKIODJYZSVHDO-JJMGAAHBSA-N,CC(C)[C@H](N(C)C)C(N[C@H](C(C)C)C(N(C)[C@H](C(N(CCC1)[C@]1([H])C(N2CCC[C@]([H])2C(NC(C)(C)C)=O)=O)=O)C(C)C)=O)=O.[H]Cl,"Melanoma,Non-Small-Cell Lung Carcinoma, Prostate Cancer","Investigated for use/treatment in Melanoma,Non-Small-Cell Lung Carcinoma, Hormone-refractory Prostate Cancer."
DCTPepD0101,Urokinase-Derived Peptide A6,Not available,Not available,C91709,A6; ACETYL-LYS-PRO-SER-SER-PRO-PRO-GLU-GLU-NH2; uPA-derived Peptide A6; urokinase plasminogen activator (uPA)-derived peptide A6; Urokinase-Derived Peptide A6,KPSSPPEE,8,"C-terminal Ac, N-terminal NH2",Not available,Not available,Not available,Peptide and derivative##Antiangiogenesis agent,Biotech,"An octapeptide (amino acids 136-143) derived from the proteolytic enzyme urokinase plasminogen activator (uPA), with potential antineoplastic activity. A6 is derived from the nonreceptor-binding domain and connecting region of urokinase. Administration of A6 inhibits the interaction of uPA with its receptor uPAR, and may inhibit endothelial cell motility and tumor cell invasion. uPA and uPAR promote extracellular matrix degradation and growth factor activation and correlate positively with angiogenesis, cancer cell invasion and metastasis.",KM64V5W7RA,220334-14-5,Not available,Not available,Not available,"Ovarian epithelial cancer, Fallopian tube cancer, Primary peritoneal cancer.","Investigated for use/treatment in persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer."
DCTPepD0106,Thymalfasin,16130571,DB04900,C1253,Thymosin Alpha 1; Zadaxin,SDAAVDTSSEITTKDLKEKKEVVEEAEN,28,C-terminal Ac,C129H215N33O55,3108.3,"(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S,3R)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]propanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]-6-aminohexanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-6-aminohexanoyl]amino]-4-carboxybutanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-4-carboxybutanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]propanoyl]amino]-5-[[(1S)-3-amino-1-carboxy-3-oxopropyl]amino]-5-oxopentanoic acid",Peptide and derivative,Biotech,"A synthetic analogue of thymosin-alpha-1, a 28-amino acid protein derived from the precursor protein prothymosin-alpha. Exhibiting a variety of immunoregulating properties, thymosin-alpha-1 induces differentiation of murine T-cell precursors and human thymocytes and the terminal differentiation of functionally immature cord blood lymphocytes and induces production of IL-2, high affinity IL-2 receptors, and B-cell growth factors by peripheral blood mononuclear cells. T-helper and cytotoxic/suppressor T-cell populations are targets of thymosin activity. Thymosin-alpha-1 has been shown to increase the efficiency of antigen presentation by macrophages and to be an endogenous modulator of alpha-thrombin activity.",W0B22ISQ1C,62304-98-7,Not available,Not available,Not available,"Chronic Hepatitis C Virus (HCV) Infection, Colorectal Cancer, Melanoma, Hepatocellular Carcinoma","Indicated as an adjuvant for influenza vaccine in elderly patients and as an adjuvant for both influenza and hepatitis B vaccines in chronic hemodialysis patients who failed to achieve adequate antibody titers from previous immunization. Investigated for use/treatment in Colorectal Cancer, Melanoma, Hepatocellular Carcinoma, among others."
